This website uses cookies to improve the functionality and performance of the website, to better understand how you use AAPA’s website and services, and to provide you with a customized experience. By continuing your use of this website, you consent to this use of cookies. See our Privacy Policy for more information.

Inside COPD: The Inflammation Behind the Disease

COPD is more than just a smoking-related disease—it’s driven by chronic inflammation involving multiple immune pathways. This video focuses on type 2 inflammation (T2I), a distinct endotype marked by eosinophilic activity and cytokine signaling, which plays a key role in exacerbations and lung damage. PA Bizik breaks down the cellular and molecular drivers of T2I and explains how recognizing this phenotype can help clinicians recognize increased exacerbation risk and personalize therapy.

Key Takeaways:

  1. COPD is characterized by chronic inflammation – both type 1 and 2 may be present.
  2. COPD is a heterogeneous disease and requires precision medicine.
  3. Type 2 inflammation in COPD is associated with a higher risk of exacerbations and hospitalization.

Previous Series Next Video

Speaker

Click on the photo below to learn more about the speaker.

Brian Bizik, MS, PA-C, DFAAPA

References and Additional Resources:

Beech A, Higham A, Booth S, Tejwani V, Trinkmann F, Singh D. Type 2 inflammation in COPD: is it just asthma? Breathe (Sheff). 2024;20(3):230229. doi:10.1183/20734735.0229-2023

Bergantini L, d’Alessandro M, Cameli P, et al. Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab. Scand J Immunol. 2021;94(1):e13031. doi:10.1111/sji.13031

Bergantini L, Pianigiani T, d’Alessandro M, et al. The effect of anti-IL5 monoclonal antibodies on regulatory and effector T cells in severe eosinophilic asthma. Biomed Pharmacother. 2023;166(115385):115385. doi:10.1016/j.biopha.2023.115385

Buchheit KM, Lewis E, Gakpo D, et al. Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2021;148(2):574-584. doi:10.1016/j.jaci.2021.05.043

Domvri K, Tsiouprou I, Bakakos P, et al. Effect of mepolizumab in airway remodeling in patients with late-onset severe asthma with an eosinophilic phenotype. J Allergy Clin Immunol. 2025;155(2):425-435. doi:10.1016/j.jaci.2024.10.024

Gandhi MA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425-437. doi:10.1080/1744666X.2017.1298443

Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Mangement, and Prevention of Chronic Obstructive Pulmonary Disease.; 2025. https://goldcopd.org/2025-gold-report/

Hamakawa M, Ishida T. Usefulness of mepolizumab for mucus plugs. Intern Med. 2024;63(22):3113-3114. doi:10.2169/internalmedicine.3531-24

Higham A, Dungwa J, Pham TH, McCrae C, Singh D. Increased mast cell activation in eosinophilic chronic obstructive pulmonary disease. Clin Transl Immunology. 2022;11(9):e1417. doi:10.1002/cti2.1417

Kolsum U, Damera G, Pham TH, et al. Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. J Allergy Clin Immunol. 2017;140(4):1181-1184.e7. doi:10.1016/j.jaci.2017.04.027

Malik B, Bartlett NW, Upham JW, Nichol KS, Harrington J, Wark PAB. Severe asthma ILC2s demonstrate enhanced proliferation that is modified by biologics. Respirology. 2023;28(8):758-766. doi:10.1111/resp.14506

Phillips KM, Lavere PF, Hanania NA, Adrish M. The emerging biomarkers in chronic obstructive pulmonary disease: A narrative review. Diagnostics (Basel). 2025;15(10):1245. doi:10.3390/diagnostics15101245

Rabe KF, Rennard S, Martinez FJ, et al. Targeting type 2 inflammation and epithelial alarmins in chronic obstructive pulmonary disease: A biologics outlook. Am J Respir Crit Care Med. 2023;208(4):395-405. doi:10.1164/rccm.202303-0455CI

Raby KL, Michaeloudes C, Tonkin J, Chung KF, Bhavsar PK. Mechanisms of airway epithelial injury and abnormal repair in asthma and COPD. Front Immunol. 2023;14:1201658. doi:10.3389/fimmu.2023.1201658

Rakkar K, Pang YL, Rajasekar P, et al. Mepolizumab-induced changes in nasal methylome and transcriptome to predict response in asthma. Am J Respir Crit Care Med. 2024;209(10):1268-1272. doi:10.1164/rccm.202308-1477LE

Sridhar S, Liu H, Pham TH, Damera G, Newbold P. Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases. Respir Res. 2019;20(1):14. doi:10.1186/s12931-018-0968-8

Taillé C, Chanez P, Devouassoux G, et al. Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme. Eur Respir J. 2020;55(6):1902345. doi:10.1183/13993003.02345-2019

Tashkin DP, Wechsler ME. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018;13:335-349. doi:10.2147/COPD.S152291

Tomomatsu K, Yasuba H, Ishiguro T, et al. Real-world efficacy of anti-IL-5 treatment in patients with allergic bronchopulmonary aspergillosis. Sci Rep. 2023;13(1):5468. doi:10.1038/s41598-023-32246-8

Xu X, Yu T, Dong L, et al. Eosinophils promote pulmonary matrix destruction and emphysema via Cathepsin L. Signal Transduct Target Ther. 2023;8(1):390. doi:10.1038/s41392-023-01634-x

Yun JH, Lamb A, Chase R, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018;141(6):2037-2047.e10. doi:10.1016/j.jaci.2018.04.010

Zheng T, Zhu Z, Wang Z, et al. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest. 2000;106(9):1081-1093. doi:10.1172/JCI10458

Supported by